ReviewJournal of medicinal chemistry2026
Discovery and Development of Voxvoganan: First-in-Class Synthetic Antimicrobial Peptidomimetic.
Review in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- RK-14: A Novel Antimicrobial Peptide Targeting Multidrug-Resistant Bacteria and Catheter-Associated Biofilms.Probiotics and antimicrobial proteins · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Voxvoganan is a synthetic antimicrobial peptidomimetic designed by applying the principles of natural antimicrobial peptides sharing many of the attractive properties, such as a wide antimicrobial spectrum and fast antimicrobial action. In contrast to the natural peptides that typically consist of 15-25 residues, voxvoganan contains only three amino acids, comparable to a classical small molecule drug, and can be manufactured on an industrial scale using solution phase methods. Voxvoganan has been developed both as a drug for the early treatment of respiratory viral infection and as an antimicrobial active pharmaceutical ingredient in medical devices to avoid microbial fouling, thus reducing the infection risk connected with the use of these devices. During development, voxvoganan has been through toxicology and safety studies as well as Phase 1 and 2 clinical studies. When voxvoganan hits the market as a first-in-class drug, the unique potential of antimicrobial peptides will finally reach patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.